Andy Mears – Chief Executive

Andy joined Deltex Medical in 1989 as an Electronics Engineer. Throughout his career with Deltex Medical, he has held a number of roles, including Production Manager and Operations Director. Andy was appointed as Group Sales Director in 2010, Managing Director 2015 and Chief Executive in 2018.

Natalie Wettler – Finance Director

Natalie commenced her Deltex Medical career in 2011 and has held a number of senior roles in the Group’s finance department between 2011 and 2016. Natalie re-joined the Group in January 2020 as Group Financial Controller and was appointed Group Finance Director in May 2021.She has a Bachelor of Science Degree in Cognitive Science from the University of Sheffield and qualified as a Chartered Accountant with Grant Thornton in the UK and continued her Grant Thornton career in New Zealand. Natalie’s experience in the medical sector also includes head of Finance for Peak Primary Limited in New Zealand in the Primary Healthcare sector.


Non-Executive Directors

Nigel Keen – Chairman

Nigel has been involved with Deltex Medical since 1988 and Chairman since 1996. He is also Chairman of MedAccess Guarantee which is a government sponsored social finance company established to make medicines more affordable in Lower and Middle Income Countries and Oxford Academic Health Science Network, established by the National Health Service in England to align the interests of patients in its region with academia, industry and the healthcare system. His career has encompassed venture capital, industry and banking. He has a degree in engineering from Cambridge University, is a Fellow of the Institute of Chartered Accountants, a Fellow of the Institute of Engineering and Technology and has been involved in the formation and development of high technology businesses for more than thirty years. Nigel is Chairman of the Remuneration Committee.

Julian Cazalet

Julian joined the Board in April 2008 and is Chairman of the Audit Committee. Julian is considered as an Independent Non-Executive director by the Board because of the quality of his judgement derived from his extensive experience of corporate boards gained throughout his career. After graduating in Economics from Cambridge he qualified as a Chartered Accountant before joining Cazenove & Co in 1973, where latterly he worked in Corporate Finance advising listed companies until retiring in 2007. He is Chairman of The Lindsell Train Investment Trust plc and of The Mary Rose Permanent Endowment Fund and a Trustee of The Greenham Trust. 

Mark Wippell

Mark, who joined the Board in 2014, has broad international commercial experience gained through working extensively with UK, North American and other overseas based companies. He is an Association Member of BUPA and a member of the CW Innovation Advisory Group supported by CW+, the official charity of the Chelsea & Westminster NHS Foundation Trust. He is a mentor on Techstars accelerator programs for early stage technology companies. He was formerly a senior corporate partner at Allen & Overy LLP, is past Chairman of the American European Business Association and was previously a member of advisory committees at Oxford University. Mark is qualified as a lawyer in the UK and the US.

Professor Tim Irish

Tim has worked in the life sciences industry for 35 years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips – the latter two in senior executive positions. Tim is a Professor of Practice at King’s College London, and Vice-Chair of the National Institute for Health and Care Excellence (NICE). Tim currently holds a number of non-executive board roles in health and digital technology related companies based in the UK, Europe, and the USA.

Terminus Road | Chichester | PO19 8TX | United Kingdom

  • Enquiries: +44 1243 774837
  • Email:
  • Deltex App:


Registered in England & Wales Company No: 1691369